Company intelligence / Profile preview

Dechra

Northwich, Cheshire, United Kingdomdechra.com ↗

Ownership: Public · DPH
Employees: ~2000
Development stage: Other

Overview

Dechra has a broad commercial portfolio of veterinary pharmaceuticals with established efficacy across endocrinology (notably trilostane for Cushing’s disease in dogs), dermatology/topicals for skin conditions, analgesics/anesthetics for pain management and surgery support in animals. The company also markets antibiotics and vaccines for livestock. Its products are widely used by veterinarians globally[3][4][5][6].

Therapeutic areas: NeurologyInfectious DiseasesDermatologyEndocrinologyWomen's Health
Modalities: Small moleculeBiologic (including hormones and peptides)ProteinHormone analog
Industry: Veterinary

Financials

Market cap: $9.5B
Total revenue: $5B
Enterprise value: $10.2B

Beyond the preview

Go deeper on Dechra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dechra.

Explore the full profile